HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target from $45 to $50.
Read original at benzingaStocks · News reference
8-K filing — MoonLake Immunotherapeutics (MLTX)
Filed: 2026-08-10 AccNo: 0001213900-26-086939 Size: 320 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 10, 2026, 11:15 AM
- Checked
- Aug 10, 2026, 11:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
MoonLake Immunotherapeutics Filed For Mixed Shelf Offering, Size Not Disclosed
Read original at benzingaMoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
Read original at benzingaMoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and
Read original at benzinga